

## Manufacturer Data - Annual Price Increase Filings for 2022

**Background:**

Under ORS 646A.689 manufacturers are required to report annually prescription drugs with a price of \$100 or more for a one month supply (or course of treatment less than one month) with a net price increase of 10 percent or more.

Drugs reported to the Oregon Drug Price Transparency (DPT) program with price increases in 2022 were reviewed and ranked by the greatest increase, most costly, and most expensive.

**Data Sources Utilized:**

Manufacturer data reported to iReg as part of the 2022 annual rate increase filings. Items marked trade secret (TS) by the manufacturer have been redacted from this report.

Medi-span price history data was also reviewed to calculate the Average Wholesale Acquisition Cost (AWAC) and for data validation and correction as needed.

Therapeutic equivalent and biosimilar information pulled from Orange Book TEE codes and Purple book reference product information. Approval dates pulled from the FDA's Orange and Purple books respectively.

**Definitions:**

Acronym	Term	Definition - how it was calculated
TS	Trade secret	The value was flagged as trade secret in iReg and has been excluded from this data set.
	Date on market	The date a given drug is first available to buy/sell in the U.S.
AWAC	Average wholesale acquisition cost	The time-weighted price average for the year 2022. Price history was reviewed in Medi-span by the Oregon DPT data analyst. Each price listed in 2022 was multiplied by the number of days spent at said price and divided by the number days of the year, then the results were for each price were added together to obtain the AWAC.
	Beginning WAC 2022	The Wholesale Acquisition Cost (WAC) reported in iReg for January 1, 2022.
	Beginning WAC 2023	The WAC listed in Medi-span at the beginning of January 2023 if the change to pricing occurred within 4 days of the end of calendar year 2022, or the December 31st WAC reported in iReg if there was not a price increase within 4 days of the end of the calendar year 2022.
	Introductory Price	The price the drug on the date of its date on market.
	Price per unit	Calculated by: AWAC / (Package Size x Package Quantity)
NIP	Net increase percentage	The percent the WAC increased from the beginning of 2022 to the beginning of 2023. Calculated by: (Beginning WAC 2023 - Beginning WAC 2022) / Beginning WAC 2022
GI	Greatest increase	Drugs with the greatest net increase percentage.
MC	Most costly	Drugs with the greatest AWAC for 2022.
ME	Most expensive	Drugs with the highest price per unit for 2022.
	Has orphan indications	Reviewed drugs for any orphan designations in the FDA Orphan Designation Database, if none were found, the drug was listed as "No". If an approved orphan designation was listed for the drug, the FDA label(s) for the drug were reviewed to determine if the drug was approved for any other indications in addition to the orphan designation. If the orphan designation was the only approved use, the drug was listed as "Orphan only". If the indications for the drug included both orphan and non-orphan approved indications, the drug was marked as "both".
	Drug has a therapeutic equivalent or biosimilar	NDC for the drug shows a therapeutic equivalence evaluation (TEE) code beginning with "A" in the orange book, or the drug has a biosimilar listed in the purple book, or is listed as a biosimilar in the purple book.
	Drug approved through an expedited pathway	The prescription drug application qualified for one or more of the following expedited approval processes: fast track approval, priority review, accelerated approval, or breakthrough therapy designation.
	Patent expiration date within 18 months	If "yes" is listed in this field, then the max patent expiration date listed for the drug application in the orange/purple book expires within the next 18 months. If "no" is listed in this field, then the max patent expiration date listed for the drug application in the orange/purple book does not expire within the next 18 months. If "no data" is listed in this field, then patent date information could not be located for the application associated with the drug.
	Exclusivity expiration date within 18 months	(For non-biologics) If "yes" is listed in this field, then the max exclusivity expiration date listed for the drug application in the orange book expires within the next 18 months. If "no" is listed in this field, then the max exclusivity expiration date listed for the drug application in the orange book does not expire within the next 18 months. If "no data" is listed in this field, then exclusivity date information could not be located for the application associated with the drug. (For biologics) the exclusivity date used was based on 12 years from the date of the initial application approval. Drugs with a date set to expire in the next 18 months were marked as "yes", others were marked as "no".
	Avg YoY price change (over past 5 years)	Average percent of the change in the year over year unit WAC for the last five years.

**Data Limitations:**

While price per unit gives a general idea of the costs associated with the drug, it may not fully capture the cost of a course of treatment.